Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
News|Slideshows|May 31, 2018
A Confluent, Crusty Rash
How would you approach diagnosis of this widespread, nonpruritic rash? Lab work? Skin tests? Or will history and physical findings suffice?
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Patient Care Online
1
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
2
Stroke Incidence Nearly Doubled Among Adults Younger Than 55 Over 3 Decades
3
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
4
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
5